DUPIXENT MyWay® Program

Help eligible patients
start and stay on treatment with
DUPIXENT MyWay®

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

You or your patients can contact
DUPIXENT MyWay
at
1-844-DUPIXEN(T)
(1-844-387-4936)

Monday-Friday, 8 am to 9 pm ET

Enrolling Your Patients in DUPIXENT MyWay

Our team can provide assistance during the insurance approval process. Support begins when your patients enroll in DUPIXENT MyWay. You can help by directing them to the DUPIXENT MyWay Enrollment Forms below. If your patients need further support, DUPIXENT MyWay Nursing Support is available as a single point of contact. Watch the video below for more information.

To enroll in DUPIXENT MyWay, your patients can call 1‑844‑DUPIXEN(T)
(1‑844‑387‑4936) or email or print and fill out the following forms with your assistance.

Putting the pieces together for acquiring DUPIXENT.

After you prescribe DUPIXENT, a correctly filled out DUPIXENT MyWay Enrollment Form helps ensure patient enrollments are processed without delays.

Forms are available at DUPIXENTHCP.com. Please ensure that you are filling out the correct form that corresponds to the appropriate indication.

First, allow the patient to review the Patient Authorization and Certifications. Then, ensure the patient has signed and dated twice at the top of the form where indicated, as it is vital to the process that the patient reads and agrees to both the Patient Authorization and the Certifications.

To help ensure a seamless enrollment process, ask the patient if they would like to provide their email address, mobile phone number, and to consent to receiving text messages.

Please inform patients that DUPIXENT MyWay will be contacting them through their preferred method of communication and that maintaining communication is important for them to receive support from DUPIXENT MyWay.

Ensure that the Healthcare Provider has read and agrees to the Healthcare Provider certification, and signs and dates the prescription at the bottom.

Populate the clinical information corresponding to your patient’s diagnosis. A list of potential codes is provided within the Enrollment Form for reference. Be sure to provide only one ICD-10 code, even if the patient has comorbid disease.

Once the primary ICD-10 code is filled in and the form is completed, write the names of the patient and prescriber at the top of all pages.

DUPIXENT MyWay complements your office’s process for accessing DUPIXENT. Your office may choose to use a preferred specialty pharmacy to start the benefits investigation.

If this is the case, write the preferred specialty pharmacy name and then check the box indicating that you have sent the prescription to the specialty pharmacy, which will be responsible for securing the coverage on the patient’s behalf.

Fax the Enrollment Form with the checked box to both the specialty pharmacy and DUPIXENT MyWay. This will allow the specialty pharmacy to conduct the benefits investigation, and DUPIXENT MyWay will provide additional support to the patient.

If your office does not use a preferred specialty pharmacy, leave the box unchecked to indicate that you would like DUPIXENT MyWay to conduct the benefits investigation on the patient’s behalf.

Fax the Enrollment Form with the unchecked box to DUPIXENT MyWay. They will begin the benefits investigation and inform your office of the next steps.

Please note that you will receive a confirmation fax after sending the form.

If the patient has consented, the patient’s Nurse Educator will initiate a welcome call with the patient within a few days after enrolling. The DUPIXENT MyWay nurse connects patients to a variety of helpful resources, including one-on-one nursing support, financial assistance for eligible patients, and helpful refill and injection reminders.

Need additional guidance with the enrollment process? Contact your Field Access Specialist or call DUPIXENT MyWay.

DUPIXENT MyWay
ENROLLMENT FORMS

FOR ALLERGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ENT SPECIALISTS/
PULMONOLOGISTS
English Enrollment Form
Spanish Enrollment Form

Coverage Support

Provides assistance navigating the insurance process.


Benefits investigation, prior authorization (PA), and appeals support

DUPIXENT MyWay verifies your patient’s specific health plan coverage for DUPIXENT, determines the plan's utilization management (UM) criteria, and identifies out-of-pocket responsibilities. If a PA is required, your DUPIXENT MyWay Coordinator can help you navigate the PA process. They will also help you and your patients understand the appeals process if coverage is denied.

How to access DUPIXENT

Learn how to navigate the approval and specialty pharmacy process to get your patients started on DUPIXENT.

Putting the pieces together for acquiring DUPIXENT.

DUPIXENT is covered under the pharmacy benefit plan, which requires a patient to coordinate delivery with a specialty pharmacy.

After a healthcare provider prescribes DUPIXENT, the patient schedules their delivery of DUPIXENT from the specialty pharmacy, pays the copay, coordinates the shipment, and can administer DUPIXENT themselves or receive the injection from a caregiver after appropriate training from their healthcare provider.

It’s important to understand the specialty pharmacy process and its role in obtaining DUPIXENT.

Many specialty medications, such as DUPIXENT, have longer turnaround times because of the prior authorization process.

When DUPIXENT is prescribed by a healthcare professional, you can work with the patient to complete the Enrollment Form, and then fax the Enrollment Form with all signatures, dates, and ICD-10 codes to DUPIXENT MyWay.

It is important that the patient consents to receiving communication from DUPIXENT MyWay and indicates how they would like to be contacted, whether it be via email, phone, or text.

Once enrolled, a benefits investigation to determine coverage begins.

It’s important to understand how to identify prescription drug coverage. Key points of contact for coverage are located on the card itself.

Some plans, including commercial and Medicare, may even have a separate pharmacy benefit card.

A Summary of Benefits Form will be faxed to your office within a few days, detailing the patient’s coverage—including prior authorization requirements and out-of-pocket costs. DUPIXENT MyWay will not conduct the benefits investigation, nor send a Summary of Benefits Form, for providers who have checked the specialty pharmacy box on the Enrollment Form, as this indicates that they wish the specialty pharmacy to conduct the benefits investigation.

The prior authorization information required by the patient’s insurance to approve coverage for DUPIXENT may include the patient’s history, medication, and clinical information.

It is important to note that a plan may deny prior authorization. There are several reasons for this, including incomplete documentation, administrative errors, clinical reasons or a no-coverage determination, or a plan exclusion.

In the case of a denial, you may consider writing an appeal, if appropriate, making sure to address the plan’s specific concerns. You can refer to DupixentHCP.com for the appeals kit, which will provide information about the process of appealing a denial, and reference sample letters provided by DUPIXENT MyWay.

In some denial cases, a plan may require a peer-to-peer review with a medical reviewer at the health plan.

If the prior authorization is reviewed by the patient’s insurance carrier and is approved, the prescription is triaged to the specialty pharmacy for fulfillment.

It is recommended that you fax a copy of prior authorization approval to DUPIXENT MyWay to help the office staff continue the process in several ways, such as:

Initiating contact with the patient regarding the approval and sharing the specialty pharmacy name and phone number.

Advising the patient to contact the specialty pharmacy for preferred delivery location.

And reminding them that the specialty pharmacy may call them from an unknown number.

Lastly, the specialty pharmacy reviews the prescription and contacts the patient to arrange for payment and delivery. If the patient is eligible for copay assistance, the patient or caregiver can then ensure the copay assistance is applied, coordinate delivery with the specialty pharmacy and access additional DUPIXENT MyWay support.

Once final approval and payment are received, the patient coordinates shipment to their home or their healthcare provider’s office, depending on treatment plan.

Remember to monitor and document the patient’s progress for reauthorization. DUPIXENT MyWay will also remind the healthcare professional when the authorization is up for reapproval.

Need additional guidance with the enrollment process? Contact your Field Access Specialist or call DUPIXENT MyWay at 1-844-387-4936, Monday through Friday, 8 am to 9 pm Eastern Time.

After you have determined DUPIXENT is appropriate for your patient and written them a prescription:

  1. Submit the DUPIXENT MyWay Enrollment Form
  2. Submit PA and Letter of Medical Necessity (optional) and include all required documentation (a copy of your chart notes with details of diagnosis, disease severity, and treatment history)
  3. Receive status updates from your DUPIXENT MyWay Coordinator

Approval

DUPIXENT MyWay representative arranges shipment with patient via specialty pharmacy (in network) or patient arranges shipment with specialty pharmacy (out of network).

Get Coverage Information

Check the formulary status of DUPIXENT in your area with our coverage tool today.

see formulary coverage data

Get a Quick Start

Get a Quick Start

For patients with commercial insurance who are new to DUPIXENT and are experiencing a coverage delay, the DUPIXENT Quick Start program may be able to help with temporary access to DUPIXENT at no cost. Ask your Field Representative for additional information.

Navigating Prior Authorizations & Appeals

Download a complete guide on coverage for DUPIXENT
Prior authorization and
appeals guide

Sample Letters

If a prior authorization is denied, you can fill out the payers appeal form, write an appeal letter, and add supporting documentation. While sample letters are included in the above guide, you can download the corresponding Microsoft Word templates to edit to your office’s needs.

LETTER OF MEDICAL NECESSITY
NON-CANDIDATE FOR SURGERY
DENIAL DUE TO SEVERITY Denial DUE TO
Non‑Formulary Status
GENERAL MEDICAL EXCEPTION

When writing letters, be sure to populate an appropriate ICD-10 code matching your patient’s diagnosis. Download our reference guide to have on hand.

ICD-10 CODE REFERENCE GUIDE
CoverMyMeds support is available for DUPIXENT

CoverMyMeds provides additional PA process-related support for DUPIXENT. Live support is available at 866‑452‑5017 or covermymeds.com

Patient Access Support

Copay Card

Eligible patients covered by commercial health insurance may pay as little as a $0a copay per fill of DUPIXENT (maximum of $13,000 per patient per calendar year).

Patients may be eligible for the DUPIXENT MyWay Copay Card if they:

  1. Have commercial insurance
  2. Have a DUPIXENT prescription for an FDA-approved condition
  3. Are a resident of the 50 United States, the District of Columbia, or Puerto Rico; and are a patient or caregiver aged 18 years or older

Send them the following link to see if they're eligible:

COPAY CARD ONLINE SIGN-UP
Patient Assistance Program

Assistance may still be available for patients who do not have insurance

  • A DUPIXENT MyWay Nurse Educator can help qualified patients explore additional options to help cover the cost of DUPIXENT
    • The Patient Assistance Program may be an option if your patient is uninsured or functionally uninsured, or experiences a gap or loss of insurance

The DUPIXENT MyWay team will research each patient’s situation and determine eligibility. For more information, call 1‑844‑DUPIXEN(T)
(1‑844‑387‑4936)
, option 1.


aTHIS IS NOT INSURANCE. Program has an annual maximum of $13,000. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DoD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional terms and conditions apply.

Nursing Support

Nurse Educators take a patient-centric approach to helping patients start and stay on therapy.


Every enrolled patient is assigned a phone-based DUPIXENT MyWay Nurse Educator, who takes a patient-centric approach to providing tools, support resources, and education throughout the patient's treatment journey.

Insightful tips and tools to help them along the way

One-on-one nursing support, when needed, to provide disease and DUPIXENT education and ongoing follow-up to ensure patients stay on track with DUPIXENT

Help scheduling deliveries of DUPIXENT

Reminder when eligible patients must reapply for financial support programs (Copay Card Program, Patient Assistance Program)

Supplemental injection training virtually or over the phone

Copay assistance for eligible patients

Monthly refill and injection reminders

Supplemental Injection Support

Along with initial training provided by the HCP's office and support from DUPIXENT MyWay Nurse Educators, your patients will also find instructional videos, patient testimonials, and downloads in our Injection Support Center.

Available Resources

  • Supplemental instructional videos will walk your patients or their caregivers through the process of administering DUPIXENT
  • They can hear from other patients who have been through the process
  • A mindful breathing exercise may help your patients achieve the right frame of mind to help calm their nerves
  • Downloadable Instructions for Use will give your patients another resource to always have at their side
View Injection Support Center

Important Safety
Information and Indications

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, erythema multiforme, anaphylaxis, and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis occurred more frequently in subjects with chronic rhinosinusitis with nasal polyposis who received DUPIXENT. There were no cases of keratitis reported in the CRSwNP development program. Among asthma subjects, the frequencies of conjunctivitis and keratitis were similar between DUPIXENT and placebo. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-Morbid Asthma: Advise patients with CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.

ADVERSE REACTIONS:

  • Asthma: The most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.
  • Chronic rhinosinusitis with nasal polyposis: The most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

DRUG INTERACTIONS:  Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1‑877‑311‑8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indications

Asthma: DUPIXENT is indicated as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic rhinosinusitis with nasal polyposis (CRSwNP): DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.